Trial Profile
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Latiglutenase (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
- Acronyms CeliAction
- Sponsors Alvine Pharmaceuticals
- 29 Aug 2017 Data published in an ImmunogenX Media Release.
- 28 Jul 2017 Results of a post hoc subgroup analysis published in the Digestive Diseases and Sciences
- 09 May 2017 Results of subgroup analysis assessing effect of latiglutenase on specific symptoms of Coeliac-disease, presented at the Digestive Disease Week 2017